Larimar Therapeutics, Inc. (LRMR)
3.85
-0.09
(-2.28%)
USD |
NASDAQ |
Sep 02, 16:00
3.85
0.00 (0.00%)
After-Hours: 20:00
Larimar Therapeutics Enterprise Value : 259.96M for Sept. 1, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 01, 2026 | 259.96M |
| August 31, 2026 | 247.43M |
| August 28, 2026 | 267.27M |
| August 27, 2026 | 271.44M |
| August 26, 2026 | 283.97M |
| August 25, 2026 | 282.92M |
| August 24, 2026 | 271.44M |
| August 21, 2026 | 285.01M |
| August 20, 2026 | 282.92M |
| August 19, 2026 | 292.32M |
| August 18, 2026 | 272.48M |
| August 17, 2026 | 299.62M |
| August 14, 2026 | 303.80M |
| August 13, 2026 | 294.40M |
| August 12, 2026 | 304.84M |
| August 11, 2026 | 298.58M |
| August 10, 2026 | 267.27M |
| August 07, 2026 | 282.92M |
| August 06, 2026 | 287.10M |
| August 05, 2026 | 276.66M |
| August 04, 2026 | 277.70M |
| August 03, 2026 | 264.13M |
| July 31, 2026 | 247.43M |
| July 30, 2026 | 247.95M |
| July 29, 2026 | 227.60M |
| Date | Value |
|---|---|
| July 28, 2026 | 248.48M |
| July 27, 2026 | 248.48M |
| July 24, 2026 | 266.22M |
| July 23, 2026 | 267.27M |
| July 22, 2026 | 268.31M |
| July 21, 2026 | 258.91M |
| July 20, 2026 | 248.48M |
| July 17, 2026 | 234.91M |
| July 16, 2026 | 231.78M |
| July 15, 2026 | 246.39M |
| July 14, 2026 | 236.99M |
| July 13, 2026 | 237.52M |
| July 10, 2026 | 295.45M |
| July 09, 2026 | 279.79M |
| July 08, 2026 | 225.51M |
| July 07, 2026 | 204.64M |
| July 06, 2026 | 192.11M |
| July 02, 2026 | 188.98M |
| July 01, 2026 | 183.76M |
| June 30, 2026 | 167.06M |
| June 29, 2026 | 137.42M |
| June 26, 2026 | 185.44M |
| June 25, 2026 | 168.74M |
| June 24, 2026 | 182.30M |
| June 23, 2026 | 187.52M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| SELLAS Life Sciences Group, Inc. | 2.532B |
| Marker Therapeutics, Inc. | 9.753M |
| Rezolute, Inc. | 314.16M |
| Krystal Biotech, Inc. | 9.931B |
| ACADIA Pharmaceuticals, Inc. | 4.090B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.78M |
| Total Expenses (Quarterly) | 32.78M |
| EPS Diluted (Quarterly) | -0.3141 |
| Earnings Yield | -51.51% |
| Normalized Earnings Yield | -51.50 |